Is an anti-Schistosoma haematobium vaccine necessary?

International Journal for Parasitology

Volumn 29, Issue 4, 1999, Pages 651-653

  El Ridi, Rashika ^a   El Garem, Ahmed A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; VACCINE;

DISEASE TRANSMISSION; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; PREVALENCE; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS; VACCINATION;

SCHISTOSOMA HAEMATOBIUM;

EID: 0033119138     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(99)00012-0     Document Type: Note

References (38)

1. Sturrock RF. The parasites and their life cycles. In: Jordan P, Webbe G, Sturrock RF, editors. Human Schistosomiasis. Wallingford: CAB International, 1993;1-32.
2. Von Lichtenberg F. Consequences of infection with schistosomes. In: Rollinson D, Simpson AJG, editors. The Biology of Schistosomes, London: Academic Press, 1987;185-232.
3. Lambertucci JR. Schistosoma mansoni: Pathological and clinical aspects. In: Jordan P, Webbe G, Sturrock RF, editors. Human Schistosomiasis. Wallingford: CAB International, 1993;195-235.
4. Farid Z. Schistosomes with terminal-spined eggs: Pathological and clinical aspects. In: Jordan P, Webbe G, Sturrock RF, editors. Human Schistosomiasis. Wallingford: CAB International, 1993; 159-93.
5. El-Garem AA. Schistosomiasis. Digestion 1998;59:589- 605.
6. Bergquist NR. Controlling schistosomiasis by vaccination: A realistic option? Parasitol Today 1995;11:191-4.
7. Bergquist NR, Colley DG. Schistosomiasis vaccines: Research to development. Parasitol Today 1998;14:99-104.
8. Wegner DHG. The profile of the trematocidal compound, praziquantel. Arzneimittel Forschung 1984;34:1132-6.
9. Wilkins HA, Blumenthal UJ, Hagan P, Hayes RJ, Tulloch S. Resistance to reinfection after treatment of urinary schistosomiasis. Trans R Soc Trop Med Hyg 1987;81:29-35.
10. Hagan P. Reinfection, exposure and immunity in human schistosomiasis. Parasitol Today 1992;8:12-16.
11. Hagan P, Chandiwana S, Ndhlovu P, Woolhouse M, Dessein A. The epidemiology, immunology and morbidity of Schistosoma haematobium infections in diverse communities in Zimbabwe. I. The study design. Trop Geog Med 1994;46:227-32.
12. Savioli L, Renganathan E, Montresor A, Davis A, Behbehani K. Control of schistosomiasis - A global picture. Parasitol Today 1997;13:444-8.
13. Butterworth AE, Hagan P. Immunity in human schistosomiasis. Parasitol Today 1987;3:11-16.
14. Chandiwana SK, Woolhouse MEJ, Bradley M. Factors affecting the intensity of reinfection with Schistosoma haematobium following treatment with praziquantel. Parasitology 1991;102:73-83.
15. Hagan P, Blumenthal UJ, Dunn D, Simpson AJG, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature Lond 1991;349:243-5.
16. Etard J-F, Audibert M, Dabo A. Age-acquired resistance and predisposition to reinfection with Schistosoma haematobium after treatment with praziquantel in Mali. Am J Trop Med Hyg 1995;52:549-58.
17. Nash TE, Cheever AW, Ottesen EA, Cook JA. Schistosome infections in humans: Perspectives and recent findings. Ann Intern Med 1982;97:740-54.
18. Wilkins HA, Gell PW, Marshall TFDC, Moore PJ. Dynamics of Schistosoma haematobium infection in a Gambian community. I. The pattern of human infection in the study area. Trans R Soc Trop Med Hyg 1984;78:216-21.
19. Wilkins HA, Gell PH, Marshall TFDC, Moore PJ. Dynamics of Schistosoma haematobium infection in a Gambian community. III. Acquisition and loss of infection. Trans R Soc Trop Med Hyg 1984;78:227-32.
20. Abdel-Salam E, Ehsan A. Cytoscopic picture of Schistosoma haematobium in Egyptian children correlated to intensity of infection and morbidity. Am J Trop Med Hyg 1978;27:774-8.
21. Cheever AW. Schistosomiasis and neoplasia. J Natl Cancer Inst 1978;61:13-18.
22. Grzych J-M, Pearce E, Cheever A et al. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J Immunol 1991;146:1322-7.
23. Pearce EJ, Caspar P, Grzych J-M, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991;173:159-66.
24. Williams ME, Montenegro S, Domingues AL et al. Leukocytes of patients with Schistosoma mansoni respond with a Th2 pattern of cytokine production to mitogen or egg antigens but with a Th0 pattern to worm antigens. J Infect Dis 1994;170:946-54.
25. Falcone FH, Dahinden CA, Gibbs BE et al. Human basophils release interleukin-4 after stimulation with Schistosoma mansoni egg antigen. Eur J Immunol 1996;26:1147-55.
26. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990;145:3796-806.
27. Seder RA, Paul WE, Davis MM, De St Groth BF. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992;176:1091-8.
28. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
29. Grogan JL, Kremsner PG, Deelder AM, Yazdanbakhsh M. Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection. Eur J Immunol 1996;26:1365-70.
30. Ndhiovu P, Cadman H, Vennervald BJ, Christensen NE, Chidimu M, Chandiwana SK. Age-related antibody profiles in Schistosoma haematobium infections in a rural community in Zimbabwe. Parasite Immunol 1996;18:181-91.
31. El Ridi R, Farouk F, Sherif M et al. T and B cell reactivity to a 42 kDa protein is associated with human resistance to both schistosomiasis mansoni and haematobium. J Infect Dis 1998;171:1364-72.
32. Medhat A, Shehata M, Bucci K et al. Increased interleukin-4 and interleukin-5 production in response to Schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment. J Infect Dis 1998;178:512-9.
33. Bliss J, Van Cleave V, Murray K et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol 1996;156:887-94.
34. Muraille E, Leo O. Revisiting the Th1/Th2 paradigm. Scand J Immunol 1998;47:1-9.
35. Actor JK, Shirai M, Kullberg MC, Buller RML, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA 1993;90:948-52.
36. Actor JF, Marshall MA, Eltoum IA, Buller RML, Berzofsky JA, Sher A. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: Association of viral persistence with egg granuloma formation. Eur J Immunol 1994;24:3050-6.
37. Curry AJ, Else KJ, Jones F, Bancroft A, Grencis RK, Dunne DW. Evidence that cytokine-mediated immune interactions induced by Schistosoma mansoni alter disease outcome in mice concurrently infected with Trichuris muris. J Exp Med 1995;181:769-74.
38. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996;173:269-72.